Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer

NCT02490748 | Active Not Recruiting Phase 2 DMC

• 1 other identifier: cervical001
• Study Type: interventional
• Target: 10
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cervical cancer.

Conditions

Cervical Cancer

Outcome Measures

Primary Outcomes (1)

• Recurrence-free survival

  Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.

  1 year

Study Arms (2)

RFA alone

NO INTERVENTION

Patients undergo radiofrequency ablation alone.

RFA+CIK

EXPERIMENTAL

Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions

Procedure: Radiofrequency ablation; Biological: Cytokine-induced killer cells

Interventions

Radiofrequency ablation PROCEDURE

Radiofrequency ablation is performed percutaneously under CT/US guidance

Also known as: RFA

RFA+CIK

Cytokine-induced killer cells BIOLOGICAL

The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.

Also known as: CIK

RFA+CIK

Eligibility Criteria

• Age: 30 Years - 70 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• They were systematic reviews based on randomized controlled trials (rcts). They were phase II rcts comparing chemotherapy with other systemic therapy agents or with no further treatment for recurrent, metastatic, or persistent cervical cancer.
• they reported at least one of these outcomes: complete or partial response rate, overall or progression-free survival rate, adverse effects, or healthrelated quality of life (rcts reporting on heterogeneous populations-for example, women at a range of disease stages-were included if results were given separately for patients with recurrent, metastatic, or persistent cervical cancer).

You may not qualify if:

• studies evaluating the role of radiotherapy administered with chemotherapy, or second- or subsequent-line therapy options.

Sponsors & Collaborators

• The First People's Hospital of Changzhou: lead

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Interventions

Radiofrequency Ablation

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Intervention Hierarchy (Ancestors)

Radiofrequency Therapy; Therapeutics; Ablation Techniques; Surgical Procedures, Operative

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 2, 2015
• First Posted: July 7, 2015
• Study Start: July 1, 2015
• Primary Completion (Estimated): June 1, 2038
• Study Completion (Estimated): June 1, 2040
• Last Updated: February 23, 2016

Record last verified: 2016-02